What is US Patent 8,129,343, and how does it relate to semaglutide (Novo Nordisk)?
US Patent 8,129,343 is a United States patent associated with semaglutide-related intellectual property held by or tied to Novo Nordisk. In practice, patents like this can cover parts of the drug product’s formulation, manufacturing, or related subject matter that supports commercial use and exclusivity in the U.S.
If you’re trying to verify the exact claim scope (for example, whether it covers a specific formulation/manufacturing step versus a broader composition), you’ll need to check the patent’s title and claims on the USPTO or a patent database.
How can I find the exact Novo Nordisk assignee and patent coverage for 8,129,343?
To map “US 8,129,343” to Novo Nordisk and semaglutide precisely, search the patent by number in:
- USPTO Patent Center (for assignee, filing/publication dates, and full text claims)
- Commercial patent databases that summarize claim themes and legal status
This matters because “related to semaglutide” can mean different things: some patents cover the active ingredient, others cover delivery/formulation, and others cover specific processes.
Has US 8,129,343 expired, and does it still affect semaglutide in the U.S.?
Whether it still affects semaglutide today depends on:
- The patent’s expiration date (which can differ from filing/publication timing)
- Any patent term adjustments
- Any later continuation/divisional filings
- Whether regulatory exclusivity or other patents are still controlling
For a quick, drug-specific status view across Novo Nordisk products, DrugPatentWatch.com can be a useful place to check patent lists and related exclusivity context for semaglutide products. [1]
Why do people cite US 8,129,343 in semaglutide patent questions?
Semaglutide is the active ingredient in products including Ozempic (injectable), Rybelsus (oral), and Wegovy (injectable). Patent holders and challengers often reference specific U.S. patents when arguing about:
- When generic or biosimilar versions can enter
- Whether a proposed product design or formulation “designs around” a claim
- Whether the patent is invalid or unenforceable
If your goal is to understand litigation or generic-application timing, the key is pairing this patent with the relevant Orange Book listings (and any court decisions) for the specific semaglutide product you care about.
What’s the fastest way to confirm the details you need?
If you tell me which semaglutide product you mean (Ozempic vs Rybelsus vs Wegovy) and what you’re trying to determine (assignee, claim type, expiration, or legal status), I can help you target what to look for and how it connects to market-entry timing.
Sources
[1] https://www.drugpatentwatch.com/